Brief: Biophytis H1 Net Loss Narrows To EUR 9.5 Million

Biophytis SA

18/09/2020 17:06

Sept 18 (Reuters) - Biophytis SA  ALBPS.PA :
    * SARA-INTEREST: TREATMENT PERIOD EXTENDED BY 3 MONTHS BASED
ON
FAVORABLE RISK PROFILE OF SARCONEOS (BIO1010) IN SARCOPENIA
PHASE 2B STUDY. LAST PATIENT OUT EXPECTED BY END 2020
    * CASH ON HAND INCREASED TO €12.2 MILLION AS OF JUNE 30TH 
2020,
AND TO €18 MILLION AS OF JULY 3 2020 FOLLOWING THE LAST CAPITAL
INCREASE
    * NEW PHASE 2/3 COVA STUDY FOR ACUTE RESPIRATORY FAILURE
ASSOCIATED WITH COVID-19
    * H1 NET LOSS EUR 9.5 MILLION VERSUS LOSS OF EUR 10.2
MILLION YEAR
AGO
    * H1 OPERATING LOSS EUR 7.5 MILLION VERSUS LOSS OF EUR 9.6
MILLION
YEAR AGO
    * MYODA CLINICAL PROGRAM IN DUCHENNE MUSCULAR DYSTROPHY
(DMD):
DEPENDING ON THE EVOLUTION OF THE PANDEMIC, THIS TRIAL MIGHT
START BY THE END OF 2020

Source text: https://bit.ly/3kuN82B
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))